In the contemporary cosmeceutical and pharmaceutical sectors, Tyrosinase Inhibitors represent one of the most commercially significant categories of active ingredients. Tyrosinase is the rate-limiting enzyme in the melanogenesis pathway, catalyzing the hydroxylation of L-tyrosine to L-DOPA and its subsequent oxidation to dopaquinone.
Currently, the global market is witnessing a paradigm shift from traditional chemical synthetics like hydroquinone toward biocompatible, plant-derived alternatives. As an OEM leader, Shaanxi Bieyouth Biotech is at the forefront of this transition, leveraging advanced extraction technologies to provide inhibitors that offer high efficacy without the cytotoxic side effects associated with earlier generations of lightening agents.
Industrial demand is particularly surging in the Asia-Pacific region, driven by the "glass skin" trend, while Western markets are increasingly utilizing these inhibitors for treating solar lentigines and post-inflammatory hyperpigmentation (PIH).
Developing biomimetic peptides that compete for the active site of tyrosinase, providing targeted delivery and enhanced stability in aqueous formulations.
Combining tyrosinase inhibition with PAR-2 inhibitors and antioxidants (like Taxifolin) to block melanin production at multiple stages.
Utilizing liposomal and nano-emulsion delivery systems to improve the percutaneous absorption of hydrophobic inhibitors like Glabridin.
Established in 2018, Shaanxi Bieyouth Biotech Co., Ltd. has consolidated its position as a Large-scale Gold Supplier in the global raw material market. We specialize in the high-precision extraction of plant and animal bioactive compounds, including pharmaceutical-grade cosmetic raw materials.
Our GMP-certified production facility features two standardized workshops equipped with industry-leading extraction technology. Our global footprint spans the USA, UK, Canada, Russia, and Australia, reflecting our commitment to international quality standards.
Foundation & Initial Extraction R&D
Global Export Launch & Institute Building
FDA Certification Accomplished
Shanghai International Exhibition Participation
Next-Gen Bio-Fermentation Synthesis
Providing high-purity tyrosinase inhibitors as active pharmaceutical ingredients (APIs) for dermatological prescriptions targeting melasma and ochronosis.
Full-cycle development from ingredient selection to private label packaging for premium skincare brands worldwide.
Innovative application of enzyme inhibitors in nutritional supplements to prevent enzymatic browning in food processing and enhance "beauty from within" products.
OEM involves manufacturing based on your specific formula and concentration, while ODM leverages our internal R&D to design a unique formulation tailored to your brand goals.
We use sophisticated stabilization techniques including cold-chain processing and micro-encapsulation to prevent oxidation and ensure efficacy throughout the shelf life.
Yes, Shaanxi Bieyouth Biotech obtained the FDA certificate in August 2023, ensuring our raw materials meet the highest safety standards for the US and international markets.
Absolutely. We can adjust the standardization (e.g., 10:1, 20:1, or specific active percentages like 98% Saponins) to meet your formulation needs.
Bieyouth
